多发性硬化症疾病修改治疗算法:2025年葡萄牙多发性硬化症研究小组的定位
Carlos Capela1, Ernestina Santos2, Filipe Palavra3
1Grupo de Estudos de Esclerose Múltipla (GEEM). Sociedade Portuguesa de Neurologia. Matosinhos. Portugal; Multiple Sclerosis Centre of Integrated Responsibility. Hospital Santo António dos Capuchos. Unidade Local de Saúde de São José. Lisbon. Portugal; Centro Clínico Académico de Lisboa. NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. Portugal.
Acta medica portuguesa
|May 6, 2025
概括
葡萄牙专家提出了更新的多发性硬化症 (MS) 治疗指南. 这旨在通过解决目前针对各种多发性硬化症亚型的国家战略的差距,将新疗法纳入并改善患者的治疗结果.
科学领域:
- 神经免疫学和神经退行性疾病
- 临床神经学和治疗学
背景情况:
- 多发性硬化症 (MS) 是一种慢性,自身免疫性神经退行性疾病,影响中枢神经系统,在葡萄牙每10万人中患病率为64.4.
- 目前的多发性硬化症治疗选择,特别是渐进性硬化症,是有限的,国家管理战略需要更新,以反映疾病修饰疗法 (DMT) 的最新进展.
研究的目的:
- 识别和解决葡萄牙现有的多发性硬化症治疗算法的缺陷.
- 提出与全球标准一致的基于证据的改进方案,以优化葡萄牙的MS管理.
- 改善葡萄牙医疗保健系统内的治疗选择和患者结果.
主要方法:
- 葡萄牙多发性硬化症研究小组的九名葡萄牙神经病学专家制定了最新的建议.
- 包括多种MS亚型的DMT算法,包括孤立综合征,复发性复发性MS (RRMS) 和渐进性MS.
- 考虑特定的患者群体,如儿科发病的MS,晚发病的MS和怀孕/母乳养期间的MS.
主要成果:
- 提供基于证据和临床实践的建议,以优化MS管理决策.
- 为各种MS亚型和临床场景提供量身定制的DMT算法.
- 强调需要紧急修订国家多发性硬化症治疗框架.
结论:
- 拟议的改进旨在使葡萄牙的多发性硬化护理与国际准则和最新的科学证据保持一致.
- 更新国家框架对于降低社会经济负担和改善葡萄牙多发性硬化患者的长期健康结果至关重要.
- 这些建议将帮助医疗保健专业人员为患有多发性硬化症的人做出明智的治疗选择.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...